Press Release
Uncertainty remains for newly diagnosed patients with mild Alzheimer’s disease and their families as the Judicial Review judgement is revealed
10 Aug 2007 - Basingstoke, UK – 10 August 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the global specialty biopharmaceutical company welcomes the decision of Judge Linda Dobbs in the Judicial Review that the National Institute for Health and Clinical Excellence (NICE) Appraisal Committee acted unlawfully by not having due regard to anti-discriminatory legislation in the formulation of their Guidance, potentially resulting in discrimination against mild patients with learning or language difficulties.
However, Shire is disappointed that the judgement in effect upholds the NICE Guidance that the majority of newly diagnosed patients with Alzheimer’s disease of mild severity should not receive drug treatments on the NHS.
NICE have been directed to prepare revised Guidance to address this issue. Until the wording of the NICE Guidance is reviewed and agreed that it has met the Judge’s directions, the practical effect of such revised guidance for clinicians and patients remains uncertain.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
